AbbVie shares fall 2.3% as RBC raises target to $330
FROM THE WIRE · FINANCE.YAHOO.COM
This article first appeared on GuruFocus. AbbVie (NYSE:ABBV) has a growth story to selland two medicines doing the heavy lifting. Shares fell 2.32% to $288.06 at 10:20 a.m. ET on November 2, even as RBC raised its price target to $330 from $280 and maintained Outperform. The…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishThe stock fell despite RBC raising its target, with Outperform maintained.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Shares fell 2.32% to $288.06 at 10:20 a.m. ET on November 2.
- 02RBC raised its target from $280 to $330 and maintained Outperform.
- 03Skyrizi and Rinvoq generated $8.482 billion in the third quarter.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets